Skip to content

Whittier Daily News

69°F
Tuesday, November 25th 2025

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Septerna, Inc. - Common Stock (NQ:SEPN)

27.39 -1.12 (-3.91%)
Streaming Delayed Price Updated: 1:53 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Septerna, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Septerna to Participate in 8th Annual Evercore Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna to Participate in Upcoming Investor Conferences
From Septerna, Inc.
Via GlobeNewswire
News headline image
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead ↗
Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments 
Via MarketBeat
Topics World Trade
News headline image
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna to Participate in Upcoming Investor Conferences
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers 
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
News headline image
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗
Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases. 
Via Benzinga
News headline image
This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Septerna In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly ↗
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
News headline image
Septerna to Present at Jefferies Global Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
News headline image
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well. 
Via MarketBeat
Topics World Trade
News headline image
Where Septerna Stands With Analysts ↗
 
Via Benzinga
News headline image
3 Stocks That Will Profit From Trump's Drug Price Cut ↗
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
News headline image
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role ↗
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic amid mixed signals. 
Via Benzinga
News headline image
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
News headline image
Which stocks have an unusual volume on Thursday? ↗
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Is It Time to Buy the Dip in Novo Nordisk Stock?
Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing 
Via MarketBeat
Topics Government
News headline image
Top movers analysis in the middle of the day on 2025-05-14: top gainers and losers in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Edges Higher; US Crude Oil Inventories Increase ↗
 
Via Benzinga
Topics Stocks
News headline image
Wednesday's pre-market session: top gainers and losers ↗
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs ↗
Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases. 
Via Benzinga
News headline image
Nasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing ↗
The deal is worth up to $2.2 billion, including more than $200 million in upfront and near-term payments. 
Via Investor's Business Daily
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.